A recently published review paper highlights TK1 as a tumor biomarker

Among other advantages the authors summarize that

  • the immunoassay of TK1 makes it a more sensitive biomarker for studying solid malignancies, thereby increasing its value as a biomarker
  • TK1 levels in malignancies are associated with clinical stage, offering potential for patient and subject stratification
  • Elevated and/or increasing serum TK1 levels after treatment indicate therapy escape


Authors are Alertix Kiran Kumar Jagarlamudi and Martin Shaw.

Read more here

Leave a Reply

Your email address will not be published. Required fields are marked *